The Manufacturers Life Insurance Company raised its position in Johnson & Johnson (NYSE:JNJ) by 11.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,080,648 shares of the company’s stock after purchasing an additional 702,986 shares during the quarter. Johnson & Johnson comprises approximately 1.0% of The Manufacturers Life Insurance Company’s investment portfolio, making the stock its 12th biggest holding. The Manufacturers Life Insurance Company owned 0.26% of Johnson & Johnson worth $907,384,000 at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in the business. Goodman Financial Corp acquired a new position in Johnson & Johnson in the 4th quarter worth approximately $104,000. Stelac Advisory Services LLC acquired a new position in Johnson & Johnson in the 4th quarter worth approximately $108,000. Princeton Capital Management LLC acquired a new position in Johnson & Johnson in the 1st quarter worth approximately $141,000. Smart Portfolios LLC acquired a new position in Johnson & Johnson in the 1st quarter worth approximately $150,000. Finally, Wrapmanager Inc. acquired a new position in Johnson & Johnson in the 4th quarter worth approximately $213,000. Institutional investors own 71.62% of the company’s stock.
A number of equities research analysts have issued reports on JNJ shares. TheStreet raised shares of Johnson & Johnson from a “c+” rating to a “b” rating in a research note on Friday, May 18th. Credit Suisse Group set a $151.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Tuesday, June 12th. Jefferies Financial Group set a $145.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Sunday, July 15th. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Finally, Sanford C. Bernstein started coverage on shares of Johnson & Johnson in a research note on Wednesday, June 27th. They set a “market perform” rating and a $129.00 target price for the company. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $142.34.
Johnson & Johnson stock opened at $133.72 on Wednesday. The firm has a market cap of $361.36 billion, a PE ratio of 18.32, a price-to-earnings-growth ratio of 2.05 and a beta of 0.69. The company has a current ratio of 1.65, a quick ratio of 1.33 and a debt-to-equity ratio of 0.47. Johnson & Johnson has a 1-year low of $118.62 and a 1-year high of $148.32.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 17th. The company reported $2.10 earnings per share for the quarter, beating analysts’ consensus estimates of $2.06 by $0.04. The business had revenue of $20.83 billion for the quarter, compared to the consensus estimate of $20.39 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. Johnson & Johnson’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter last year, the firm earned $1.83 EPS. research analysts expect that Johnson & Johnson will post 8.14 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 11th. Stockholders of record on Tuesday, August 28th will be issued a dividend of $0.90 per share. The ex-dividend date of this dividend is Monday, August 27th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.69%. Johnson & Johnson’s dividend payout ratio is currently 49.32%.
In other news, COO Michael E. Sneed sold 29,000 shares of the firm’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the transaction, the chief operating officer now owns 59,124 shares in the company, valued at approximately $7,969,915.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.22% of the stock is currently owned by company insiders.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: Market Capitalization in the Stock Market
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.